Bioinformatics analysis of basal and luminal cancer for diagnostic biomarkers

Abstract

There are more than 1.15 million cases of breast cancer diagnosed worldwide annually. Only a few reliable prognostic and predictive factors are currently applied in clinical practice to the treatment of breast cancer patients. The simultaneous evaluation of the expression of thousands of genes is a capability of DNA microarrays. Recent preliminary studies suggest that gene expression profiling using a DNA microarray can potentially provide patients with newly diagnosed breast cancer with independent prognostic information. An overview of the uses of microarray techniques in breast cancer is provided in this study and compare basal and luminal BC using the microarray aspect at two levels of miRNA and genes. Our results showed that 221 gene probes could be a significant differential expressed genes in breast cancer and only seven of miRNAs were differentially expressed. The genes represented in ETS1, ZEB1, EMP1, PRSS23, TFPI, NAV2, ACSL4, IGFBP3, TUBB2A, NPNT and MYB were highly differential expressed in basal breast cancer compared to luminal breast cancer and these genes were interacted with hsa-miR-429, hsa-miR-34a and hsa-miR-200b which these miRNAs were downregulated in basal breast cancer. These genes and miRNAs could be a diagnostic or prognostic biomarker need investigation in further study.